US-based specialist pharmaceutical company Heron Therapeutics has raised $200m through an underwritten public offering of shares of its common stock.
The underwriters will receive a 30-day option to buy additional shares worth $30m.
The company plans to use the funds towards the commercialisation of its drugs HTX-011, SUSTOL and CINVANTI. The funds are also intended to be used for product development activities and other general corporate purposes.
Gibson, Dunn & Crutcher was the legal adviser to the company for the offering.
EyePoint Pharmaceuticals plans for the private placement of a second tranche of units to raise $25.5m under a securities purchase agreement with Essex Woodland (EW) Healthcare Partners.
The company will offer and sell an aggregate of more than $25.5m-worth units to the second tranche investors. Each unit consists of one share of common stock and a warrant to purchase a share of common stock.
Based in the US, EyePoint Pharmaceuticals is a specialist pharmaceutical company engaged in the development of innovative drug products.
The funds from the offering will be used towards EyePoint’s transformation into a commercial-stage specialist biopharmaceutical company.
Celgene Corporation has partnered with Skyhawk Therapeutics to develop and commercialise small molecules targeting ribonucleic acid (RNA) mis-splicing in neurological diseases.
Celgene Corporation is a biotechnology company focused on the discovery and development of medicines for cancer and inflammatory disorders, while Skyhawk Therapeutics is engaged in the discovery and development of therapies to build small molecule drugs using its novel platform, STAR.
Both companies involved in the transaction are based in the US.
The agreement enables the two companies to provide small molecule treatment options for patients with neurological diseases.
WuXi Biologics has formed a strategic collaboration with Harbour BioMed to develop and manufacture the latter’s leading HCAb antibody.
The collaboration will focus on the supply of Harbour’s products for clinical trials following the investigational new drug (IND) applications in China and other countries.
The collaboration is WuXi Biologics’ first project based on a novel format of heavy chain only antibodies (HCAb).
WuXi Biologics is a pharmaceutical manufacturing company, while Harbour BioMed is a biotechnology company engaged in the discovery and development of therapeutics for cancer.
Both companies involved in the transaction are based in China.
The partnership allows the two companies to provide HCAb antibodies in China and the rest of the world.